Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia Inhibitory Factor Development in Oncology and Fibrosis.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LIF pathway drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LIF Recombinant Protein Human/Mouse/Cyno Orthologs. HEK293 Expressed, High Purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View LIF Products |
| Gene Delivery | LIF Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV/EF1a promoter options. |
View LIF Products |
| Benchmark Ab | Anti-LIF Benchmark Antibody Recombinant positive control for neutralizing assays. Sequence Verified. |
View LIF Products |
| Validator | LIF siRNA Set (3 target-specific + 1 control) For knockdown and specificity verification. |
View LIF Products |
| LIFR (Receptor) | LIFR ECD-Fc Fusion Primary receptor complex partner. Essential for binding assays. |
View LIFR Products |
| IL6ST (gp130) (Co-receptor) | IL6ST / gp130 Protein Co-receptor for LIF signaling, crucial for specificity screening. |
View IL6ST Products |
| OSM (Family Member) | OSM Recombinant Protein Shared gp130/LIFR pathway member for specificity testing. High Purity. |
View OSM Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Neutralization Assays | High-purity human LIF and LIFR ECD-Fc, Endotoxin Controlled (<1 EU/µg) for robust IC50 determination |
| Cross-Species Efficacy Evaluation | Human, Mouse, and Cyno ortholog proteins available (>95% purity) for seamless preclinical transition |
| Specificity vs. IL-6 Family (OSM, IL-6, CNTF) | Homolog panel proteins (OSM, IL-6) for counter-screening; strict mass spec verification |
| False Positives / Off-target | Validated LIF siRNA set for genetic validation of assay specificity |
Live LIF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
LIF (Leukemia Inhibitory Factor) has emerged as a critical target in the tumor microenvironment, driving cancer stem cell maintenance and chemotherapy resistance, particularly in pancreatic ductal adenocarcinoma (PDAC), glioblastoma, and triple-negative breast cancer (TNBC). Simultaneously, its role in pulmonary and hepatic fibrosis is gaining traction. The current pipeline is dominated by neutralizing monoclonal antibodies (e.g., AstraZeneca/Northern Biologics' MSC-1, Regeneron's anti-LIF mAb), with early-phase candidates exploring combination strategies with immune checkpoint inhibitors and chemotherapy. As the field matures, focus is shifting toward LIF receptor (LIFR) modulation, bispecific antibodies targeting the LIF/gp130 axis, and small molecule inhibitors for fibrotic indications (IPF, NASH). The next wave of R&D is expected to emphasize combination therapies to reverse tumor microenvironment exclusion and overcome compensatory activation of IL-6 family members.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-LIF mAb | AstraZeneca, Northern Biologics, Regeneron, iTeos | Pancreatic Cancer, Glioblastoma, TNBC | Neutralization Assay (Need high-purity LIF & LIFR for IC50) |
| Anti-LIFR mAb | Academic / Preclinical | Fibrosis, Solid Tumors | Receptor-Ligand Competition (Need LIFR ECD-Fc) |
| Bispecific Antibody | Early Stage Innovators | Solid Tumors (TME targeted) | Dual-binding Validation (Need ortholog proteins) |
| Small Molecule Inhibitor | Academic/Biotech, Preclinical | Refractory Cancers, IPF, NASH | Signaling Pathway / pSTAT3 Reporter Assay (Need pure recombinant cytokines) |